361 Capital LLC purchased a new stake in ChemoCentryx Inc (NASDAQ:CCXI) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 46,343 shares of the biopharmaceutical company’s stock, valued at approximately $644,000. 361 Capital LLC owned approximately 0.08% of ChemoCentryx as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently made changes to their positions in CCXI. Rhumbline Advisers raised its stake in ChemoCentryx by 44.9% during the fourth quarter. Rhumbline Advisers now owns 30,596 shares of the biopharmaceutical company’s stock worth $334,000 after acquiring an additional 9,479 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of ChemoCentryx by 70.5% during the third quarter. Dimensional Fund Advisors LP now owns 547,771 shares of the biopharmaceutical company’s stock worth $6,922,000 after purchasing an additional 226,485 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of ChemoCentryx during the fourth quarter worth $196,000. Raymond James & Associates bought a new stake in shares of ChemoCentryx during the fourth quarter worth $133,000. Finally, Vanguard Group Inc grew its holdings in shares of ChemoCentryx by 7.3% during the third quarter. Vanguard Group Inc now owns 1,329,494 shares of the biopharmaceutical company’s stock worth $16,805,000 after purchasing an additional 90,899 shares during the last quarter. 58.14% of the stock is owned by institutional investors and hedge funds.
In other news, CFO Susan M. Kanaya sold 35,000 shares of the firm’s stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $13.05, for a total transaction of $456,750.00. Following the sale, the chief financial officer now owns 110,890 shares of the company’s stock, valued at $1,447,114.50. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Thomas J. Schall sold 5,755 shares of the firm’s stock in a transaction dated Friday, March 29th. The stock was sold at an average price of $14.00, for a total value of $80,570.00. Following the sale, the chief executive officer now directly owns 2,234,610 shares in the company, valued at approximately $31,284,540. The disclosure for this sale can be found here. Insiders sold 246,570 shares of company stock worth $3,313,980 in the last three months. Insiders own 12.20% of the company’s stock.
CCXI has been the topic of several research analyst reports. Svb Leerink restated an “outperform” rating on shares of ChemoCentryx in a report on Thursday, February 14th. Zacks Investment Research cut ChemoCentryx from a “buy” rating to a “hold” rating in a report on Tuesday, February 26th. ValuEngine cut ChemoCentryx from a “strong-buy” rating to a “buy” rating in a report on Tuesday, March 5th. TheStreet cut ChemoCentryx from a “c” rating to a “d-” rating in a report on Monday, March 18th. Finally, B. Riley upgraded ChemoCentryx from a “neutral” rating to a “buy” rating and raised their price target for the company from $12.50 to $22.00 in a report on Wednesday, March 27th. Four equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. ChemoCentryx has a consensus rating of “Buy” and an average price target of $17.71.
ChemoCentryx stock traded down $0.34 during mid-day trading on Friday, hitting $8.34. The stock had a trading volume of 228,600 shares, compared to its average volume of 473,761. ChemoCentryx Inc has a 12 month low of $8.06 and a 12 month high of $14.98. The company has a quick ratio of 3.43, a current ratio of 3.43 and a debt-to-equity ratio of 0.24. The stock has a market cap of $504.44 million, a price-to-earnings ratio of -11.04 and a beta of 1.37.
ChemoCentryx (NASDAQ:CCXI) last released its earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.01. ChemoCentryx had a negative return on equity of 111.15% and a negative net margin of 97.22%. The firm had revenue of $8.33 million for the quarter, compared to analyst estimates of $11.37 million. As a group, sell-side analysts expect that ChemoCentryx Inc will post -0.92 EPS for the current year.
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis.
Read More: Resistance Level
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.